Harris Associates L P Regeneron Pharmaceuticals, Inc. Transaction History

Harris Associates L P

$76.6 Trillion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $705,630 - $836,992	-1,008 Reduced 53.45%	878 $630,000
Q1 2023 May 15, 2023	SELL	$680.49 - $826.97 $59.7 Million - $72.6 Million	-87,753 Reduced 97.9%	1,886 $1.55 Million
Q4 2022 Feb 14, 2023	SELL	$705.89 - $766.39 $69.6 Million - $75.5 Million	-98,537 Reduced 52.36%	89,639 $64.7 Million
Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $226 Million - $286 Million	-394,450 Reduced 67.7%	188,176 $130 Million
Q2 2022 Aug 15, 2022	SELL	$548.35 - $738.84 $280 Million - $377 Million	-510,391 Reduced 46.7%	582,626 $344 Million
Q1 2022 May 16, 2022	SELL	$595.12 - $698.43 $136 Million - $159 Million	-228,302 Reduced 17.28%	1,093,017 $763 Million
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $2.7 Million - $3.34 Million	-4,977 Reduced 0.38%	1,321,319 $834 Million
Q3 2021 Nov 15, 2021	SELL	$574.03 - $680.96 $68.2 Million - $80.9 Million	-118,757 Reduced 8.22%	1,326,296 $803 Million
Q2 2021 Aug 16, 2021	BUY	$472.8 - $558.54 $195 Million - $230 Million	411,475 Added 39.81%	1,445,053 $807 Million
Q1 2021 May 17, 2021	BUY	$446.73 - $548.2 $226 Million - $277 Million	505,448 Added 95.71%	1,033,578 $489 Million
Q4 2020 Feb 16, 2021	SELL	$478.3 - $607.98 $66.1 Million - $84 Million	-138,165 Reduced 20.74%	528,130 $255 Million
Q3 2020 Nov 16, 2020	SELL	$544.75 - $658.21 $306 Million - $369 Million	-560,926 Reduced 45.71%	666,295 $373 Million
Q2 2020 Aug 14, 2020	SELL	$493.32 - $643.92 $538 Million - $702 Million	-1,089,797 Reduced 47.03%	1,227,221 $765 Million
Q1 2020 May 15, 2020	SELL	$336.18 - $494.43 $689 Million - $1.01 Billion	-2,049,828 Reduced 46.94%	2,317,018 $1.13 Billion
Q4 2019 Feb 14, 2020	BUY	$274.13 - $376.51 $61.8 Million - $84.9 Million	225,394 Added 5.44%	4,366,846 $1.64 Billion
Q3 2019 Nov 14, 2019	BUY	$273.46 - $318.39 $62 Million - $72.2 Million	226,733 Added 5.79%	4,141,452 $1.15 Billion
Q2 2019 Aug 14, 2019	BUY	$299.6 - $414.82 $374 Million - $518 Million	1,247,748 Added 46.79%	3,914,719 $1.23 Billion
Q1 2019 May 15, 2019	SELL	$372.08 - $439.57 $128 Million - $151 Million	-344,437 Reduced 11.44%	2,666,971 $1.1 Billion
Q4 2018 Feb 14, 2019	SELL	$335.82 - $403.04 $54.5 Million - $65.4 Million	-162,236 Reduced 5.11%	3,011,408 $1.12 Billion
Q3 2018 Nov 14, 2018	BUY	$351.14 - $408.51 $8.77 Million - $10.2 Million	24,967 Added 0.79%	3,173,644 $1.28 Billion
Q2 2018 Aug 14, 2018	BUY	$284.6 - $344.99 $412 Million - $500 Million	1,448,644 Added 85.21%	3,148,677 $1.09 Billion
Q1 2018 May 15, 2018	BUY	$315.82 - $393.78 $537 Million - $669 Million	1,700,033 New	1,700,033 $585 Million

Others Institutions Holding REGN

# of Institutions

1,534

Shares Held

83.6M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Harris Associates L P, based on Form 13F filings with the SEC.

News

Stay updated on Harris Associates L P with notifications on news.

Account